Shanghai Jinhe Bio-Technology Co., Ltd. is a high Bio-Tech private enterprise dedicated to developing, manufacturing and marketing Anti-Cancer APIs and their intermediates.


Jinhe was established in March 2002. Based on the R&D achievement of FUDAN university, at the beginning it launched the international business of processing Paclitaxel API. After severalyears of development, we has been emerging as the largest processor on Taxus biomass in China. Afterwards, we successfully developed Docetaxel Anhydrous( Trihydrate), Irinotecan HCl Trihydrate, Etoposide and other products, developing Anti-cancer products from nature extracting to semi-synthetical Anti-cancer products. In recent two years we additionally developed Fludarabine Phosphate, Palonosetron Hydrochloride and so on, developed Anti-cancer from botanical raw materials to broad-spectrum Anti-cancer drug.


Since its establishment, we have been positioning our core value as specialization, aiming to go for internationalization, striving to cultivate own core competitiveness. Especially in respect of the effective use of Yew biomass and of the extraction, purification, synthesization of its active components. Jinhe has been in leading position and in possession of its own independent patented technique.


Our main products include Paclitaxel, Docetaxel Anhydrous (Trihydrous), Irinotecan HCl Trihydrate, Etoposide, Fludarabine Phosphate, Palonosetron Hydrochloride, 10 DAB III, Podophyllotoxin etc. These products are mainly used for Anti-cancer drugs production, with a view to benefit the numerous cancer patients.